PTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership - Action News 5 - Memphis, Tennessee

PTC Therapeutics Announces that Stuart W. Peltz, Ph.D., CEO is the Recipient of the 2014 Dr. Sol J. Barer Award for Vision, Innovation and Leadership

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE PTC Therapeutics, Inc.

SOUTH PLAINFIELD, N.J., Jan. 30, 2014 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) is proud to announce that its founder and Chief Executive Officer, Stuart W. Peltz, Ph.D. has been awarded the 2014 Dr. Sol J. Barer Award for Vision, Innovation, and Leadership. Named for Sol J. Barer, Ph.D., founder and former Chairman and Chief Executive Officer of Celgene Corporation of Summit, N.J., the award recognizes outstanding research and business leaders who have made significant contributions to the growth and prosperity of the biosciences industry in New Jersey and throughout the world.

(Logo: http://photos.prnewswire.com/prnh/20010919/PTCLOGO )

"It is an honor to receive an award named for someone who has accomplished so much for the industry and epitomizes the elements of a successful leader," stated Stuart W. Peltz, Ph.D., CEO of PTC Therapeutics, Inc. "I am grateful for this honor."

Dr. Barer, the former Chairman of Celgene Corporation and a past Chairman of BioNJ, will present the award to Dr. Peltz during ceremonies celebrating BioNJ's 21st Annual Dinner Meeting and Networking Event, which will be held today from 4:30 p.m. to 10:00 p.m. at the Hilton East Brunswick.

"Known for his pioneering research into RNA biology while at the Department of Molecular Genetics and Microbiology at the Robert Wood Johnson Medical School, Rutgers University, Dr. Peltz recognized the potential of post transcriptional mechanisms to advance medical science and help patients in need," said Dr. Barer.

"Dr. Peltz's groundbreaking research has informed the development of new therapeutic options for a wide-range of disorders," said Francois Nader, M.D., President and CEO of NPS Pharmaceuticals of Bedminster and Chairman of the BioNJ Board of Trustees. "His passion for scientific innovation exemplifies the spirit of the Dr. Sol J. Barer Award and the BioNJ Board of Trustees is proud to present Dr. Peltz with this well-deserved honor."

ABOUT THE DR. SOL J. BARER AWARD:
The Dr. Sol J. Barer Award for Vision, Innovation, and Leadership was established by the BioNJ Board of Trustees in March 2008 in an effort to recognize the outstanding research and business leaders who have made and continue to make significant contributions to the growth of the biosciences in New Jersey and around the world. The honoree is voted on by the BioNJ Board of Trustees from a recommendation based on nominations received by the Nominating Committee. The award is named for Sol J. Barer, Ph.D., who founded the biotechnology group at Celanese that was subsequently spun out to form Celgene, currently one of the world's largest biotechnology companies.

ABOUT PTC THERAPEUTICS, INC.:
PTC is a biopharmaceutical company focused on the discovery and development of orally administered, proprietary small molecule drugs that target post-transcriptional control processes. Post-transcriptional control processes regulate the rate and timing of protein production and are essential to proper cellular function. PTC's internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. PTC has developed proprietary technologies that it applies in its drug discovery activities and collaborations with leading biopharmaceutical companies. For more information on the company, please visit our website www.ptcbio.com

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow